Optomed Launches Next-Generation Handheld Fundus Camera to Power the Future of Oculomics in Everyday Healthcare

Optomed has announced the launch of Optomed Lumo®, a next-generation handheld fundus camera designed to bring retinal imaging and the emerging science of oculomics into everyday healthcare settings.
Oculomics is a growing field focused on using the retina to detect signs of systemic disease. With Optomed Lumo, the company aims to make this technology more accessible, particularly in primary care, community clinics, and non-specialist environments. With this launch, Optomed is delivering on its vision to enable screening for all by equipping primary care clinics, community health centers, and non-specialist settings with the tools to easily detect early signs of systemic disease.
Non-mydriatic Optomed Lumo sets a new standard for efficiency in retinal diagnostics with its programmable workflows, intuitive user guidance and seamless integration into various medical workflows. Designed with input from healthcare professionals, this fundus camera offers intuitive operation with high-quality imaging and AI-enhanced diagnostic platforms, allowing for faster decision-making.
Optomed Lumo is MDR Class IIa CE certified medical device. Initial deliveries are expected to begin in Q3 2025 in selected markets, with a broader rollout planned in subsequent quarters.
About Optomed
Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim of transforming the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US, and China, and the company’s products are sold via various sales channels in over 60 countries globally.
Source: Optomed